Controlling placebo response in drug development: Lessons learned from psychopharmacology

Pharmaceutical Medicine

Volumn 28, Issue 2, 2014, Pages 53-65

  Potter, William Z ^a   Mallinckrodt, Craig H ^b   Detke, Michael J ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DEVELOPMENT; EXPERIMENTAL THERAPY; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS (TOPIC); NERVOUS SYSTEM; OUTCOME ASSESSMENT; PATIENT SELECTION; PLACEBO EFFECT; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SELECTION BIAS; SELF CONCEPT; SELF REPORT; SIGNAL DETECTION; SINGLE BLIND PROCEDURE; STUDY DESIGN; THERAPY EFFECT;

EID: 84900557582     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.1007/s40290-014-0052-8     Document Type: Review

References (94)

1. Yang H, Cusin C, Fava M. Is there a placebo problem in anti-depressant trials? Curr Top Med Chem. 2005;5(11):1077-86. (Pubitemid 41582121)
2. Mallinckrodt CH, Tamura RN, Tanaka Y. Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials. J Psychiatr Res. 2011;45(9):1202-7.
3. Mallinckrodt CH, Meyers AL, Prakash A, et al. Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacol Bull. 2007;40(2):101-14.
4. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2010;(1):CD003974.
5. Khan A, Detke M, Khan SR, Mallinckrodt CH. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003;191(4):211-8. (Pubitemid 36522920)
6. Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry. 2011;72(4):464-72.
7. Hurko O, Ryan JL. Translational research in central nervous system drug discovery. NeuroRx. 2005;2(4):671-82. (Pubitemid 41393274)
8. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-5. (Pubitemid 39173511)
9. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840-7. (Pubitemid 34303629)
10. Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications to the US Food and Drug Administration. J Clin Psychiatry. 2012;73(6):856-64.
11. Arrowsmith J. Phase II failures: 2008-2010. Nat Rev Drug Discov. 2011;10:328.
12. Arrrowsmith J. Phase III and submission failures 2007-2010. Nat Rev Drug Discov. 2011;10:87.
13. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development success rates for investigational drugs. Clin Pharmacol Ther. 2010;87:272-7.
14. Gelenberg AJ, Thase ME, Meyer RE, et al. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry. 2008;69(10):1513-28.
15. World Health Organization. The global burden of disease: 2004 update. http://www.who.int/healthinfo/global-burden-disease/GBD-report-2004update-full. pdf. Accessed 7 Jan 2014.
16. Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov. 2013;12(3):191-204.
17. Chan AW, Hróbjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291(20):2457-65. (Pubitemid 38669189)
18. Khan A, Khan SR, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology. 2003;28(3):552-7.
19. Papakostas Gl, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34-40.
20. Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010;36(3):504-9.
21. Mallinckrodt CH, Zhang L, Prucka WR, et al. Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull. 2010;43(1):53-72.
22. Sinyor M, Levitt AJ, Cheung AH, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled meta-analyses. J Clin Psychiatry. 2010;71(3):270-9.
23. Mallinckrodt CH, Raskin J, Wohlreich MM, et al. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF-ANCOVA in eight clinical trials. BMC Psychiatry. 2004;4:26.
24. Rutherford BR, Sneed JR, Roose SP. Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom. 2009;78(3):172-81.
25. Noble LM, Douglas BC, Newman SP. What do patients expect of psychiatric services? A systematic and critical review of empirical studies. Soc Sci Med. 2001;52(7):985-98. (Pubitemid 32065780)
26. Sotsky SM, Glass DR, Shear MT, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry. 1991;148(8):997-1008.
27. Nakamura Y, Donaldson GW, Kuhn R, et al. Investigating dose-dependent effects of placebo analgesia: a psychophysiological approach. Pain. 2012;153(1):227-37.
28. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-60.
29. Gram LF, Pedersen OL, Kristensen CB, et al. Drug level monitoring in psychopharmacology: usefulness and clinical problems, with special reference to tricyclic antidepressants. Ther Drug Monit. 1982;4(1):17-25. (Pubitemid 12141006)
30. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(12):1140-7. (Pubitemid 36084059)
31. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.
32. Trivedi MH, Rush H. Does a placebo run-in or placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology. 1994;11(1):33-43. (Pubitemid 24277736)
33. Landin R, Debrota DJ, DeVries TA, et al. The impact of restrictive entry criterion during the placebo lead-in period. Biometrics. 2000;56(1):271-8. (Pubitemid 30165119)
34. Chen JA, Papakostas GI, Youn SJ, et al. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry. 2011;72(12):1669-76.
35. Faries DE, Heiligenstein JH, Tollefson GD, et al. The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J Clin Psychopharmacol. 2001;21(6):561-8. (Pubitemid 33116654)
36. Fava M, Evins AE, Dorer DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-27. (Pubitemid 36469860)
37. Ivanova A, Tamura RN. A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal. Stat Methods Med Res. 2011;. doi:10.1177/0962280211431023.
38. Tamura RN, Huang X. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Clin Trials. 2007;4(4):309-17. (Pubitemid 47572263)
39. Doros G, Pencina M, Rybin D, et al. A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. Stat Med. 2013;32(16):2767-89.
40. Chen YF, Yang Y, Hung HM, et al. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. Contemp Clin Trials. 2011;32(4):592-604.
41. Papakostas GI, Vitolo OV, Ishak WW, et al. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012;73:1541-7.
42. Papakostas GI, Shelton RC, Zajecka JM, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012;169:1267-74.
43. Fava M, Mischoulon D, Iosifescu D, et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom. 2012;81:87-97.
44. Marshall RD, Leigh-Pemberton RA, Memisoglu A, et al. Opioid modulation: a novel mechanism for the treatment of depression: results of the ALKS 5461 phase 2 study. 2013 ISCTM Autumn conference, Philadelphia; 2013.
45. Faes C, Molenberghs G, Aerts M, et al. The effective sample size and an alternative small sample degrees of freedom method. Am Stat. 2009;63:389-99.
46. Liu KS, Snavely DB, Ball WA, et al. Is bigger better for depression trials? J Psychiatr Res. 2008;42(8):622-30. (Pubitemid 351626061)
47. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
48. Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry. 2007;190:287-92. (Pubitemid 46580676)
49. Guico-Pabia CJ, Musgnung J, Pedersen R, et al. Placebo response in trials of antidepressants in patients with major depressive disorder. 50th NCDEU annual meeting, Boca Raton; 2010.
50. Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res. 1993;27(3):259-73. (Pubitemid 23344947)
51. Bech P, Kajdasz DK, Porsdal V. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology (Berl). 2006;188(3):273-80. (Pubitemid 44387455)
52. Maier W, Philipp M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Rating States. Pharmacopsychiatry. 1985;18:114-5. (Pubitemid 15137667)
53. McIntyre RS, Konarski JZ, Mancini DA, et al. Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. CMAJ. 2005;173(11):1327-34.
54. Nelson JC, Portera L, Leon AC. Assessment of outcome in depression. J Psychopharmacol. 2006;20(4 Suppl):47-53. (Pubitemid 44576658)
55. Faries D, Herrera J, Rayamajhi J, et al. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res. 2000;34(1):3-10. (Pubitemid 30006935)
56. Entsuah R, Shaffer M, Zhang J. A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects. J Psychiatr Res. 2002;36(6):437-48. (Pubitemid 35254119)
57. Meyers MA. Happy accidents: serendipity in modern medical breakthroughs. 1st ed. New York: Arcade Publishing; 2007.
58. Klein DF, Davis JM. Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins; 1969. p. 240-7.
59. Morris JB, Beck AT. The efficacy of antidepressant drugs. Arch Gen Psychiatry. 1974;30(5):667-74.
60. Brown WA. Predictors of placebo response in depression. Psychopharmacol Bull. 1988;24(1):14-7.
61. Elkin E, Shea T, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry. 1989;46(11):971-82. (Pubitemid 19278225)
62. Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry. 1989;46(1):89-99. (Pubitemid 19038412)
63. Wilcox CS, Cohn JB, Linden RD, et al. Predictors of placebo response: a retrospective analysis. Psychopharmacol Bull. 1992;28(2):157-62.
64. Khan A, Kolts RL, Thase ME, et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry. 2004;161(11):2045-9. (Pubitemid 39441405)
65. Khan A, Brodhead AE, Kolts RL, et al. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res. 2005;39(2):145-50. (Pubitemid 39602638)
66. Peciña M, Stohler CS, Zubieta JK. Neurobiology of placebo effects: expectations or learning? Soc Cogn Affect Neurosci. 2013 (Epub ahead of print).
67. Conboy LA, Macklin E, Kelley J, et al. Which patients improve: characteristics increasing sensitivity to a supportive patient-practitioner relationship. Soc Sci Med. 2010;70(3):479-84.
68. Tang TZ, DeRubeis RJ, Hollon SD, et al. Personality change during depression treatment: a placebo-controlled trial. Arch Gen Psychiatry. 2009;66(12):1322-30.
69. Feltner D, Hill C, Lenderking W, et al. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial. J Psychiatr Res. 2009;43:1224-30.
70. Hróbjartsson A, Kaptchuk TJ, Miller FG. Placebo effect studies are susceptible to response bias and to other types of biases. J Clin Epidemiol. 2011;64(11):1223-9.
71. Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE. 2010;5(12):e15591.
72. Rabinowitz J. Improving efficiency of RCT's of antidepressant trials: lessons learned from the NewMeds Repository of RCT data from AstraZeneca, Janssen, Eli Lilly, Lundbeck, and Pfizer. 52nd NCDEU annual meeting, Phoenix; 2012.
73. Kok RM. What is the role of medications in late life depression? Psychiatr Clin North Am. 2013;36(4):597-605.
74. Gildengers AG, Houck PR, Mulsant BH, et al. Course and rate of antidepressant response in the very old. J Affect Disord. 2002;69(1-3):177-84. (Pubitemid 34722883)
75. Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1413-22.
76. Gelwicks, SC, Debrota DJ, Engelhardt N, et al. 42nd NCDEU annual meeting, Boca Raton; 2002.
77. Chen YF, Wang SJ, Khin NA, et al. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm Stat. 2010;9(3):217-29.
78. Detke MJ, Williams JBW, Kobak KA, et al. The challenge of subject selection in clinical trials: new data. 50th NCDEU annual meeting, Boca Raton; 2010.
79. Sachs GS, Vanderburg DG, Edman S, et al. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection. J Clin Psychiatry. 2012;73(11):1420-5.
80. Debrota D, et al. A comparison between Interactive Voice Response System-administered HAM-D and clinician-administered HAM-D in patients with major depressive episode. 39th NCDEU annual meeting, Boca Raton; 1999.
81. Glaudin V, Smith WT, Ferguson JM, et al. Discriminating placebo and drug in generalized anxiety disorder (GAD) trials: single vs. multiple raters. Psychopharmacol Bull. 1994;30(2):175-8. (Pubitemid 24331383)
82. Kobak KA, Lipsitz JD, Feiger AD, et al. Same versus different raters and rater quality in a clinical trial of major depressive disorder: impact on placebo response and signal detection. 2009 ISCTM Autumn conference, San Diego; 2009.
83. Debrota D, Gelwicks S, Potter W. Same rater versus different raters in depression clinical trials. 42nd NCDEU annual meeting, Boca Raton; 2002.
84. Londborg P, et al. Is the single-rater design superior in clinical trials of anxiety? 45th NCDEU annual meeting, Boca Raton; 2005.
85. Kobak KA, Feiger AD, Lipsitz JD. Interview quality and signal detection in clinical trials. Am J Psychiatry. 2005;162(3):628. (Pubitemid 40343943)
86. Demitrack MA, Faries D, Herrera JM, et al. The problem of measurement error in multisite clinical trials. Psychopharmacol Bull. 1998;34(1):19-24. (Pubitemid 28176297)
87. Kobak KA, Leuchter A, Debrota D, et al. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacol. 2010;30(2):193-7.
88. Williams JBW, et al. Placebo response assessed by site and remote blinded centralized raters in a GAD trial. 50th NCDEU annual meeting, Boca Raton; 2010.
89. Coric V, Goddard A, Oren D, et al. A randomized, double-blind, placebo-controlled and active comparator trial of pexacerfont, a corticotropin releasing factor receptor-a antagonist, in the treatment of generalized anxiety disorder. 47th annual meeting American College of Neuropsychopharmacology, Scottsdale; 2008.
90. Friedman JH. Pimavanserin phase III PDP results ACP-103-012. 62nd American Academy of Neurology annual meeting, Toronto; 2010.
91. Shen JHQ, Zhao Y, Rosenzweig-Lipson S, et al. A 6-week randomized, double-blind, placebo-controlled, comparator referenced, multicenter trial of vabicaserin in subjects with acute exacerbation of schizophrenia. 50th ACNP annual meeting, Waikoloa Beach; 2011.
92. Brown B, De Santi S, Detke MJ, et al. Assessing interview quality and scoring accuracy in clinical trials with CQC. 49th ACNP annual meeting, Miami Beach; 2010.
93. Targum SD, Wedel P, Robinson J, et al. A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of major depressive disorder. J Psychiatr Res. 2013;47:944-54.
94. Wesnes KA, Edgar C, Dean AD, et al. The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. Epilepsy Behav. 2009;14:522-8.